免疫检测点抑制剂治疗非小细胞肺癌脑转移研究现况及进展
Research Current Status and Progress of Immune Checkpoint Inhibitors in the Treat-ment of Non-Small Cell Lung Cancer with Brain Metastases
DOI: 10.12677/ACM.2023.133521, PDF,   
作者: 黄 劲, 张 莉*：新疆医科大学第一附属医院干部保健中心，新疆 乌鲁木齐
关键词: 非小细胞肺癌；免疫检测点抑制剂；脑转移；Non-Small Cell Lung Cancer； Immune Checkpoint Inhibitors； Brain Metastasis
摘要: 目的：免疫检查点抑制剂(ICIs)用于非小细胞肺癌(NSCLC)脑转移(BMs)仍有争议。本研究旨在探讨ICIs对合并脑转移的NSCLC的疗效。评估脑转移对ICIs结果的影响。方法：通过查阅大量国内外文献，以确定评估ICIs对NSCLC脑转移的疗效或脑转移与ICIs结果之间关系。结论：ICIs作为单一治疗策略或与其他治疗(即化疗或其他具有不同机制的ICI)联合，已成为无靶向驱动基因改变的NSCLC的标准治疗。ICIs作为单一治疗可能对活动性脑转移有效。
Abstract: Objective: The use of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) with brain metastases (BMs) remains controversial. The objective of this study was to investigate the ef-ficacy of ICIs in NSCLC with brain metastases and evaluate the effect of brain metastases on ICIs outcomes. Methods: A large number of domestic and foreign literatures were reviewed to deter-mine the efficacy of ICIs in treating BMS in NSCLC or the relationship between BMS and ICIs results. Conclusions: ICIs has become the standard treatment for NSCLC without targeted driver changes as a single treatment strategy or in combination with other treatments (i.e., chemotherapy or ICI with different mechanisms). ICIs may be effective as a monotherapy for active BMS.
文章引用：黄劲, 张莉. 免疫检测点抑制剂治疗非小细胞肺癌脑转移研究现况及进展[J]. 临床医学进展, 2023, 13(3): 3638-3642. https://doi.org/10.12677/ACM.2023.133521

参考文献

[1] 盛佳敏, 俞晓晴, 李晖, 范云. PD-1/PD-L1抑制剂治疗NSCLC脑转移的免疫机制与临床研究进展[J]. 中国肺癌杂志, 2020, 23(11): 976-982.
[2] Li, W. and Yu, H. (2020) Separating or Combining Immune Checkpoint Inhibitors (ICIs) and Radiotherapy in the Treatment of NSCLC Brain Metastases. Journal of Cancer Research and Clinical Oncol-ogy, 146, 137-152. [Google Scholar] [CrossRef] [PubMed]
[3] Li, J., Wang, M., Xu, S., et al. (2022) The Strategies and Mech-anisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. Frontiers in Pharmacology, 13, Article ID: 841623. [Google Scholar] [CrossRef] [PubMed]
[4] Eguren-Santamaria, I., Sanmamed, M.F., Goldberg, S.B., et al. (2020) PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clinical Cancer Research, 26, 4186-4197. [Google Scholar] [CrossRef] 
[5] Ohe, Y., Imamura, F., Nogami, N., et al. (2019) Osimertinib versus Standard-of-Care EGFR-TKI as First-Line Treatment for EGFRm Advanced NSCLC: FLAURA Japanese Subset. Japanese Journal of Clinical Oncology, 49, 29-36. [Google Scholar] [CrossRef] [PubMed]
[6] Duruisseaux, M., Martínez-Cardús, A., Calleja-Cervantes, M.E., et al. (2018) Epigenetic Prediction of Response to Anti-PD-1 Treatment in Non-Small-Cell Lung Cancer: A Multicentre, Ret-rospective Analysis. The Lancet Respiratory Medicine, 6, 771-781. [Google Scholar] [CrossRef] 
[7] Goldberg, S.B., Schalper, K.A., Gettinger, S.N., et al. (2020) Pembrolizumab for Management of Patients with NSCLC and Brain Metastases: Long-Term Results and Biomarker Analysis from a Non-Randomised, Open-Label, Phase 2 Trial. The Lancet Oncology, 21, 655-663. [Google Scholar] [CrossRef] 
[8] Mansfield, A.S., Aubry, M.C., Moser, J.C., et al. (2016) Temporal and Spatial Discordance of Programmed Cell Death-Ligand 1 Expression and Lymphocyte Tumor Infiltration between Paired Primary Lesions and Brain Metastases in Lung Cancer. Annals of Oncology, 27, 1953-1958. [Google Scholar] [CrossRef] [PubMed]
[9] Galea, I., Bechmann, I. and Perry, V.H. (2007) What Is Immune Privilege (Not)? Trends in Immunology, 28, 12-18. [Google Scholar] [CrossRef] [PubMed]
[10] Berghoff, A.S. and Preusser, M. (2015) The Inflammatory Microen-vironment in Brain Metastases: Potential Treatment Target? Chinese Clinical Oncology, 4, 21.
[11] Noy, R. and Pollard, J.W. (2014) Tumor-Associated Macrophages: From Mechanisms to Therapy [Published Correction Appears in Immunity. 2014 Nov 20, 41(5): 866]. Immunity, 41, 49-61. [Google Scholar] [CrossRef] [PubMed]
[12] Lorger, M. and Felding-Habermann, B. (2010) Capturing Changes in the Brain Microenvironment during Initial Steps of Breast Cancer Brain Metastasis. The American Journal of Pathology, 176, 2958-2971. [Google Scholar] [CrossRef] [PubMed]
[13] Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. [Google Scholar] [CrossRef] [PubMed]
[14] Mansfield, A.S., Herbst, R.S., de Castro, G., et al. (2021) Outcomes with Pembrolizumab Monotherapy in Patients with Pro-grammed Death-Ligand 1-Positive NSCLC with Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. JTO Clinical and Research Reports, 2, Article ID: 100205. [Google Scholar] [CrossRef] [PubMed]
[15] Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., et al. (2020) Updated Analysis from KEYNOTE-189: Pembrolizumab or Placebo plus Pemetrexed and Platinum for Previously Un-treated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38, 1505-1517. [Google Scholar] [CrossRef] 
[16] Abdulhaleem, M., Johnston, H., D’Agostino, R., et al. (2022) Local Control Outcomes for Combination of Stereotactic Radiosurgery and Immunotherapy for Non-Small Cell Lung Cancer Brain Metastases. Journal of Neuro-Oncology, 157, 101-107. [Google Scholar] [CrossRef] [PubMed]
[17] LeCompte, M.C., Hughes, R.T., Farris, M., et al. (2020) Impact of Brain Metastasis Velocity on Neurologic Death for Brain Metastasis Patients Experiencing Distant Brain Failure after Initial Stereotactic Radiosurgery. Journal of Neuro-Oncology, 146, 285-292. [Google Scholar] [CrossRef] [PubMed]
[18] Sun, C., Zhou, F., Li, X., et al. (2020) PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases. OncoTargets and Therapy, 13, 12777-12786. [Google Scholar] [CrossRef] 
[19] Taube, J.M., Klein, A., Brahmer, J.R., et al. (2014) Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clinical Cancer Research, 20, 5064-5074. [Google Scholar] [CrossRef] 
[20] Le, A., Mohammadi, H., Mohammed, T., et al. (2022) Local and Distant Brain Control in Melanoma and NSCLC Brain Metastases with Concurrent Radiosurgery and Immune Checkpoint Inhibition. Journal of Neuro-Oncology, 158, 481-488. [Google Scholar] [CrossRef] [PubMed]
[21] van Bussel, M.T.J., Beijnen, J.H. and Brandsma, D. (2019) In-tracranial Antitumor Responses of Nivolumab and Ipilimumab: A Pharmacodynamic and Pharmacokinetic Perspective, a Scoping Systematic Review. BMC Cancer, 19, 519. [Google Scholar] [CrossRef] [PubMed]

为你推荐